Placebo for ASPAVELI 1 080 mg solution for infusion, ASPAVELI 1 080 mg solution for infusion
APL2-C3G-310
Phase 3 small_molecule active
Quick answer
Placebo for ASPAVELI 1 080 mg solution for infusion, ASPAVELI 1 080 mg solution for infusion for complement 3 glomerulopathy (C3G)/immune complex membranoproliferative glomerulonephritis (IC-MPGN) is a Phase 3 program (small_molecule) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pharma Mar S.A.
- Indication
- complement 3 glomerulopathy (C3G)/immune complex membranoproliferative glomerulonephritis (IC-MPGN)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active